Skip to main content

新闻和事件

-

IBA Business Update – Third Quarter 2022

Louvain-La-Neuve, Belgium, 17 November 2022 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2022.   Group Overview Business operations continue to be strong, with good performance across all four business units Exceptional group order intake of EUR 260 million at 30 September for 2022 to date, compared to EUR 133 million for the first nine months of 2021, driven by strong performance across the business, particularly within Industrial Solutions Backlog remains high at EUR 1.2 billion and new tenders continue to progress internationally for all business units Strong balance sheet with (unaudited) net cash position of EUR 134 million (30 June 2022: 137 million)   Olivier Legrain, Chief Executive Officer of IBA commented: “IBA has continued to see solid performance in the third quarter across all business units, both in terms of contract wins, technological advances and supported by targeted value driving acquisitions. We have been especially pleased to see continued momentum in Industrial Solutions, with the business unit passing a key milestone of EUR 100 million order intake to date this year. Within proton therapy we are seeing market dynamics shifting favorably with demand building in all regions globally and resulting in IBA winning strategically significant, high-value contracts. Looking ahead, whilst some challenges remain, the strategies and investments we are making are positively impacting and we are confident in the longer-term performance of the Group, underpinned by a strong balance sheet that we will continue to utilize for investment in future growth.”   Proton Therapy 24 projects ongoing in Proton Therapy, with nine Proteus®PLUS1 and 15 Proteus®ONE1 systems in progress An active global pipeline, highlighting the strength of proton therapy market across all geographies A total of 40 service contracts now generating recurring revenues globally IBA qualified as the only supplier for the second round of significant tender to provide ten proton therapy units across Spain Multi-year research collaboration signed with Fred Hutchinson Cancer Center and the University of Washington (UW), Seattle, for ConformalFLASH®2 Proton Therapy Collaboration agreement signed with Apollo Hospitals Enterprise Ltd (AHEL) The PROTECT-trial consortium enrolled the first patient in a trial investigating proton therapy in oesophageal cancer Other Accelerators (RadioPharma, Industrial) Other Accelerators continued to perform strongly in Q3, with eight new systems sold in the period. A total of 29 systems have been sold in the first nine months of 2022, compared to 23 for the same period last year Exceptional performance by Industrial Solutions, with the business reaching the milestone of EUR 100 million order intake to date Collaboration deal agreed with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone® IKON in Chengdu, Sichuan Province, China Agreement signed with NorthStar Medical Radioisotopes for two additional Rhodotron® electron beam accelerators for commercial production of radioisotopes Launched Pantera, a joint venture with SCK CEN to produce actinium-225, one of the most promising alpha-emitting radioisotopes to fight cancers Contract for the installation of an integrated radiopharmaceutical production facility in Georgia, signed post-period end Post-period, contract with Sweden Ghana Medical Centre signed for an IntegraLab® PLUS in Ghana   Dosimetry Signed a strategic alliance for radiation therapy dosimetry solutions with ScandiDos A.B. (SDOS.ST) and made a minority investment in the company IBA’s dosimetry solutions were made compatible with Halcyon® and Ethos™ radiotherapy and adaptive therapy solutions, post-period end Expanded IBA’s myQA® iON technology into Radiation Therapy, post-period end   Outlook IBA has continued to perform well across all business units in 2022 to date and this momentum is expected to persist for the remainder of the year and beyond. The pipeline remains highly active in all businesses, underpinning visibility for the period ahead. Whilst some supply chain and inflation related challenges remain, we are seeing gradual improvements and as a business, we continue to mitigate macroeconomic pressures. With an exceptionally strong balance sheet, we are continuing with our extensive investment plan to bolster our infrastructure, supply chain and logistics, reinforce our digital ambitions and continue to maintain our market-leading technology. Alongside this, we will look to seek value-enhancing opportunities to drive future sustainable growth.   Financial calendar Full Year Results 2023                                              23 March 2023 Business Update First Quarter 2023                        18 May 2023 General Assembly                                                     14 June 2023     Proteus®PLUS and Proteus®ONE are brand names of Proteus 235 ConformalFLASH® is a registered brand of IBA’s Proton FLASH irradiation solution currently under research and development phase.    
查看更多
-

IBA expands its activities in Sub-Saharan Africa and signs contract with Sweden Ghana Medical Centre for an IntegraLab® PLUS in Accra, Ghana

New contract to provide broader access to diagnostics in emerging markets   Louvain-La-Neuve, Belgium, October 13, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announces a new contract with Sweden Ghana Medical Centre (SGMC) for an IntegraLab® PLUS in Accra, Ghana. SGMC is a leading private cancer care center focused on providing the highest quality cancer treatment in West Africa. The contract marks IBA’s increasing presence in the region with operations in 21 countries.   IntegraLab® PLUS is a fully integrated solution that combines equipment and services for establishing a radiopharmaceutical GMP production center, tailored to each customer’s specific needs. The contract includes the delivery of an IntegraLab® solution, consisting of the installation and integration of a Cyclone® KIUBE 100 with Synthera® Extension, Synthera®+ HPLC and IFP loader. Sweden Ghana Medical Center will benefit from IBA's expertise for the complete setting-up of its radiopharmacy.   This contract follows several others signed in Tanzania and South Africa, and further highlights IBA’s ambition to broaden access to cancer diagnostics and treatments in regions of the world with low population density and limited access to healthcare. The demand for diagnostic and therapeutic equipment in Africa is rapidly growing, with cancer cases rising to over 800 000 cases* per year in Sub-Saharan Africa.   This latest announcement follows IBA’s launch of the Cyclone® KEY in January this year, which will provide more widespread global access to diagnostic solutions in oncology, neurology and cardiology as it answers a demand from the African market for a compact radiopharmaceuticals production solution.   Olivier Legrain, Chief Executive Officer at IBA, commented: “This contract marks an important milestone for IBA as we expand the use of our technology into emerging markets such as Africa. Continued innovation from our RadioPharma Solutions Business Unit is vital to providing patients with access to much needed diagnostics and treatments, something that is core to IBA’s mission and reinforced by the continued development of our technology. We look forward to working with SGMC and to helping them to achieve their mission of being at the forefront of cancer care in Africa.”   Dr. Clement Edusa, CEO and Medical Director at Sweden Ghana Medical Centre, added: “At SGMC, our vision is to provide the best possible cancer care across West Africa. The IntegraLab® will allow us to provide the most innovative diagnostic imaging tests to our patients, with the hope that we can identify disease and therefore start an appropriate course of treatment much quicker. IBA’s technology, not only provides us with a cost efficient and user-friendly cyclotron system but also tailored solutions that meet our specific needs, allowing us to provide the best possible care to our patients.”   *https://gco.iarc.fr/today/data/factsheets/populations/971-sub-saharan-africa-hub-fact-sheets.pdf
查看更多

了解我们

基于35年的经验, IBA放射性药物解决方案帮助核医学科设计、建造和运营PET中心,生产用于检测和治疗癌症及其他严重疾病的放射性药物。

IBA与您并肩合作并在整个过程中提供直接的支持,从第一次会议开始,到设计,到安装,到运营。除此之外,您的IBA专家将在放射性药物的整个生命周期内为您提供培训、系统更新和维护支持,以确保您的项目获得成功,实现未来可持续发展。

了解更多
Who we are

重要事件

<strong>30</strong> Ci(最多)

每次生产运行

用于FDG 生产

<strong>3</strong>个模块(最多)

在一个热室中

多种示踪剂生产,多次运行

超过<strong>800</strong> 家客户

Synthera® 放射合成模块安装遍布全球

超过<strong>300</strong>家客户

回旋加速器运行和支持服务遍布5个洲